Satoris

By Adam Bonislawski
A Stanford University-led research team has identified plasma proteins linked to declines in neurogenesis and impaired learning and memory.

RBM acquired biomarker-related IP for Alzheimer's disease and other central nervous system conditions.

Satoris will use a panel of 500 signaling proteins and antibody-based quantitative nitrocellulose filter membrane array technology to search for candidate biomarkers for the disease. In May, it launched its first commercial products, protein panels for Alzheimer's disease and dementia.

According to Satoris, the 189-marker panel covers the "most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development … [and] and thus provide researchers with critical biological information plus leads for further study."

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.